Cooper E H, Armitage T G, Robinson M R, Newling D W, Richards B R, Smith P H, Denis L, Sylvester R
Unit for Cancer Research, University of Leeds, UK.
Cancer. 1990 Sep 1;66(5 Suppl):1025-8. doi: 10.1002/cncr.1990.66.s5.1025.
Serum prostate-specific antigen (PSA) levels were studied in the EORTC trial of zoladex plus flutamide versus orchidectomy in metastatic prostatic cancer. Forty-four of 60 patients had a decrease of PSA to less than or equal to 10 ng/ml at 3 to 6 months after treatment. The combination of a PSA less than 10 ng/ml after 3 to 6 months treatment and less than 15 spots on the bone scintigram at entry gave the highest probability of not having progressed by 24 months. A rising PSA anticipated bone progression by 6 to 12 months in 13 of 28 patients (46%). The PSA at entry to the trial was related to survival; a discriminant of 300 ng/ml distinguished a poor and better risk group. The lowest level of PSA reached during the first 6 months of treatment was also a univariate survival factor.
在欧洲癌症研究与治疗组织（EORTC）进行的一项关于转移性前列腺癌的试验中，研究了血清前列腺特异性抗原（PSA）水平。该试验对比了戈舍瑞林加氟他胺与睾丸切除术的疗效。60例患者中有44例在治疗后3至6个月时PSA降至小于或等于10 ng/ml。治疗3至6个月后PSA小于10 ng/ml且入组时骨闪烁显像显示骨转移灶少于15个的患者，在24个月时疾病无进展的概率最高。28例患者中有13例（46%）PSA升高预示骨转移将在6至12个月后出现。试验入组时的PSA水平与生存率相关；以300 ng/ml为界可区分出高风险组和低风险组。治疗前6个月期间达到的最低PSA水平也是一个单变量生存因素。
